/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Citius Oncology Inc share price today is $0.8918, up -2.47%. The stock opened at $0.93 against the previous close of $0.933, with an intraday high of $0.9496 and low of $0.88.

style

pb-0

Citius Oncology Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.8918 -0.0247(-2.47%) CTOR at 13 Mar 2026 12:35 PM Drug Manufacturers - Specialty & Generic

Lowest Today 0.88

Highest Today 0.9496

Today’s Open 0.93

Prev. Close 0.933

52 Week High 6.19

52 Week Low 0.55

Day’s Range: Low 0.88 High 0.9496

52-Week Range: Low 0.55 High 6.19

Citius Oncology Inc Institutional Holdings

Citius Oncology Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Citius Oncology Inc Fundamentals

Market Cap 82.36 M

PB Ratio 1.41

PE Ratio 0.0

Enterprise Value 78.87 M

Total Assets 100.94 M

Volume 251967

Citius Oncology Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M

Annual Profit FY25:null 0.0M, FY24:null 0.0M

Annual Net worth FY25:-24761369 -24.8M, FY24:-21148747 -21.1M

Quarterly Revenue Q4/2025:3944111 3.9M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M

Quarterly Profit Q4/2025:3154903 3.2M, Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q4/2024:null 0.0M

Quarterly Net worth Q4/2025:-5534069 -5.5M, Q3/2025:-4996656 -5.0M, Q2/2025:-5369956 -5.4M, Q1/2025:-7735552 -7.7M, Q4/2024:-6659205 -6.7M

About Citius Oncology Inc & investment objective

Company Information Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Organisation Drug Manufacturers - Specialty & Generic

Employees 0

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Leonard L. Mazur

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*